TY  - JOUR
AU  - Afshar-Oromieh, Ali
AU  - Sattler, Lars Peter
AU  - Mier, Walter
AU  - Hadaschik, Boris A
AU  - Debus, Jürgen
AU  - Holland-Letz, Tim
AU  - Kopka, Klaus
AU  - Haberkorn, Uwe
TI  - The Clinical Impact of Additional Late PET/CT Imaging with (68)Ga-PSMA-11 (HBED-CC) in the Diagnosis of Prostate Cancer.
JO  - Journal of nuclear medicine
VL  - 58
IS  - 5
SN  - 2159-662X
CY  - New York, NY
PB  - Soc.
M1  - DKFZ-2017-01094
SP  - 750 - 755
PY  - 2017
AB  - Although PET/CT with (68)Ga-PSMA-11 in the diagnosis of prostate cancer (PCa) is routinely performed at 1 h after injection, later scans may be beneficial because most lesions present with higher uptake and contrast. This evaluation aimed to investigate the clinical impact of additional late (68)Ga-PSMA-11 PET/CT. Methods: Between 2011 and 2016, 112 patients with PCa who underwent early (at 1 h after injection) and late (at 3 h after injection) (68)Ga-PSMA-11 PET/CT scans were retrospectively evaluated. The late scans were conducted to clarify unclear findings in early scans or to increase the probability of tumor detection in the case of negative early scans. All patients were asked to drink 1 L of water between early and late scans. In addition, 20 patients received 20 mg of furosemide before late scans. Tumor detection and radioactivity concentration within the urinary bladder were analyzed in both scans. The SUVmax and contrast of 149 tumor lesions were measured in 69 patients with pathologic findings. Results: Overall, 134 lesions characteristic for PCa in 57 patients clearly presented at 1 h after injection and 147 lesions in 68 patients at 3 h after injection. Forty-three patients showed no pathologic findings. Eight patients (7.1
KW  - (68Ga)Glu-urea-Lys(Ahx)-HBED-CC (NLM Chemicals)
KW  - Organometallic Compounds (NLM Chemicals)
KW  - Radiopharmaceuticals (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:28062595
DO  - DOI:10.2967/jnumed.116.183483
UR  - https://inrepo02.dkfz.de/record/120668
ER  -